semaglutide and low platelets GLP-1 Agents Showed Broader Risks, Rewards in 2025 What You Need to Know

Blood 125 , 284295 (2015)

These include direct cardiac effects (protection against myocardial ischaemia, reduction of epicardial adipose tissue and improvement of cardiac contractility), vascular (vasodilator effect and improvement of endothelial dysfunction), renal (reduced glomerular filtration rate and proteinuria drop) and metabolic (blood pressure decreased, lipid profile improved and glucose-lowering effect) ( Inflammation plays a crucial role in the development and progression of atherosclerosis and its cardiovascular complications ( Considering what has previously been discussed, the primary objective of this study was to perform a systematic review and updated meta-analysis on the anti-inflammatory effect of semaglutide

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

Metabolic acidosis in the critically ill: part 1

Glutathione for skin brightening